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BACKGROUND AND PURPOSE
5-Lipoxygenase (5-LO) is the key enzyme in the biosynthesis of pro-inflammatory leukotrienes (LTs) representing a potential
target for pharmacological intervention with inflammation and allergic disorders. Although many LT synthesis inhibitors are
effective in simple in vitro test systems, they frequently fail in vivo due to lack of efficacy. Here, we attempted to assess the
pharmacological potential of the previously identified 5-LO inhibitor 2-(4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-
ylthio)octanoic acid (HZ52).
EXPERIMENTAL APPROACH
We evaluated the efficacy of HZ52 in vivo using carrageenan-induced pleurisy in rats and platelet-activating factor
(PAF)-induced lethal shock in mice. We also characterized 5-LO inhibition by HZ52 at the cellular and molecular level in
comparison with other types of 5-LO inhibitor, that is, BWA4C, ZM230487 and hyperforin.
KEY RESULTS
HZ52, 1.5 mg·kg-1 i.p., prevented carrageenan-induced pleurisy accompanied by reduced LTB4 levels and protected mice
(10 mg·kg-1, i.p.) against PAF-induced shock. Detailed analysis in cell-based and cell-free assays revealed that inhibition of
5-LO by HZ52 (i) does not depend on radical scavenging properties and is reversible; (ii) is not impaired by an increased
peroxide tone or by elevated substrate concentrations; and (iii) is little affected by the cell stimulus or by phospholipids,
glycerides, membranes or Ca2+.
CONCLUSIONS AND IMPLICATIONS
HZ52 is a promising new type of 5-LO inhibitor with efficacy in vivo and with a favourable pharmacological profile. It
possesses a unique 5-LO inhibitory mechanism different from classical 5-LO inhibitors and seemingly lacks the typical
disadvantages of former classes of LT synthesis blockers.
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Introduction
Leukotrienes (LTs) are local-acting messengers involved in the
regulation of the immune system and are associated with
inflammatory, allergic and cardiovascular disorders (Peters-
Golden and Henderson, 2007). There is also increasing evi-
dence for a pivotal role of LTs in various types of cancer
(Wang and Dubois, 2010). Accordingly, these LT-related dis-
eases might be susceptible to anti-LT agents, and LT receptor
antagonists are used for treatment of asthma and allergic
rhinitis (Peters-Golden and Henderson, 2007; Back, 2009).
The first two steps in LT biosynthesis from arachidonic acid
(AA) are catalysed by the nonhaeme iron-containing
5-lipoxygenase (5-LO), which is expressed mainly in leuco-
cytes (Radmark et al., 2007). The AA that is liberated from
phospholipids in the nuclear membrane by cytosolic PLA2
(cPLA2) is converted by 5-LO into LTA4 with the help of
5-LO-activating protein (FLAP). Further metabolism into LTB4
or the cysteinyl LTs C4, D4 and E4 occurs via additional
enzymes. 5-LO is composed of a catalytic domain and a
C2-like domain at the N-terminus; the latter domain is
involved in binding of several regulatory factors, namely
Ca2+, phosphatidylcholine (PC) vesicles, 1-oleoyl-2-acetyl-sn-
glycerol (OAG) and coactosine-like protein (Radmark et al.,
2007) and these components can compromise 5-LO inhibi-
tion (Feisst et al., 2009). Activation of 5-LO is mediated by
Ca2+ and/or phosphorylation by members of the MAPK
family, and 5-LO product formation requires the presence of
lipid hydroperoxides (LOOH) that oxidize the active site iron
to the ferric form (Fe3+) (Radmark et al., 2007).
Different strategies to inhibit excessive LT formation have
been pursued so far [for review, see Pergola and Werz (2010)].
Besides inhibition of cPLA2 and FLAP, strong efforts have been
made to find direct 5-LO inhibitors and four classes of com-
pounds can be categorized: (i) redox-active compounds that
uncouple the catalytic cycle of 5-LO by reducing the active
site iron; (ii) iron ligand inhibitors such as BWA4C or zileu-
ton; (iii) nonredox-type inhibitors that compete with AA or
LOOH for binding to the enzyme (e.g. ZM230487); and (iv)
structurally diverse 5-LO inhibitors, supposed to act in an
allosteric manner such as hyperforin that interferes with the
C2-like domain (Feisst et al., 2009). Although a number of
those compounds were promising drug candidates in pre-
clinical studies, most of them were not effective in patients or
failed in clinical studies due to unwanted side effects (Werz
and Steinhilber, 2005). Currently, zileuton is the only 5-LO
inhibitor available on the market. However, the pathophysi-
ological actions of LTs in prevalent diseases like asthma, car-
diovascular diseases and cancer urge the identification of new
concepts to interfere with 5-LO and LT formation.
We have previously presented a series of a-substituted
derivatives of pirinixic acid as novel and potent inhibitors of
5-LO (Koeberle et al., 2008; Werz et al., 2008). Previous
structure-activity relationship (SAR) studies showed that
introduction of a biphenyl moiety at position 6 of the pyri-
midine ring improved the 5-LO inhibitory potency leading to
consistent IC50 values between 0.4 and 2 mM in cell-free and
cell-based models (Koeberle et al., 2008). Here, we present
the evaluation of the lead 2-(4-(biphenyl-4-ylamino)-6-
chloropyrimidin-2-ylthio)octanoic acid (HZ52; Figure 1A) in
vivo and we provide a detailed pharmacological characteriza-
tion of HZ52 as a 5-LO inhibitor using cell-based and cell-free
assays.
Methods
Materials
HZ52 and its corresponding ethyl carboxylate HZ49 were
synthesized as described previously (Koeberle et al., 2008).
BWA4C and ZM230487 and BWA4C were generous gifts from
Dr R. M. McMillan (Zeneca Pharmaceuticals, Macclesfield,
UK) and by Dr L. G. Garland (Wellcome Res. Laboratories),
respectively. AA, Ca2+ ionophore A23187, dithiothreitol
(DTT), N-formyl-methionyl-leucyl-phenylalanine (fMLP),
LPS, 1-oleoyl-2-acetyl-sn-glycerol (OAG), PC and phosphati-
dylserine (PS) and all other fine chemicals were from Sigma
(Deisenhofen, Germany), unless stated otherwise. 13-HpODE
and LTB4 enzyme immunoassay (EIA) kit were from Cayman
Chemicals (Ann Arbor, MI, USA); adenosine deaminase (Ada)
and HPLC solvents were from Merck (Darmstadt, Germany).
l-Carrageenan type IV isolated from Gigartina aciculaire and
Gigartina pistillata was purchased from Sigma-Aldrich (Milan,
Italy). Zileuton was purchased from Sequoia Research Prod-
ucts (Oxford, UK).
Animals
Male adult Wistar Han rats (200–220 g; Harlan, Milan, Italy)
and adult CD-1 mice (25–30 g; Harlan, Milan, Italy) were
housed in a controlled environment and provided with stan-
dard rodent chow and water. Animal care complied with
Italian regulations on protection of animals used for experi-
mental and other scientific purpose (Ministerial Decree
116192) as well as with the European Economic Community
regulations (Official Journal of E.C. L 358/1 12/18/1986).
Carrageenan-induced pleurisy in rats
HZ52 (1.5 mg·kg-1) or zileuton (10 mg·kg-1) were given i.p.
30 min before carrageenan. Another group of rats received the
vehicle (DMSO, 4%, i.p.) 30 min before carrageenan. Rats were
anaesthetized with enflurane 4% mixed with O2, 0.5 L·min-1,
N2O 0.5 L·min-1 and submitted to a skin incision at the level of
the left sixth intercostal space. The underlying muscle was
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dissected, and saline (0.2 mL) or l-carrageenan type IV 1%
(w v-1, 0.2 mL) was injected into the pleural cavity. The skin
incision was closed with a suture, and the animals were
allowed to recover. At 4 h after the injection of carrageenan,
the animals were killed by inhalation of CO2. The chest was
carefully opened, and the pleural cavity was rinsed with 2 mL
of saline solution containing heparin (5 U·mL-1). The exudate
and washing solution were removed by aspiration, and the
total volume was measured. Any exudate that was contami-
nated with blood was discarded. The amount of exudates was
calculated by subtracting the volume injected (2 mL) from the
total volume recovered. Leucocytes in the exudates were resus-
pended in PBS and counted with an optical light microscope in
a Burker’s chamber after vital trypan blue staining. The
amounts of LTB4 in the supernatant of centrifuged exudate
(800¥ g for 10 min) were assayed by EIA (Cayman Chemical,
Ann Arbor, MI, USA) according to manufacturer’s protocol.
The results are expressed as nanograms per rat and represent
the mean  SEM of 10 rats.
Platelet-activating factor-induced shock
Platelet-activating factor (PAF) C-16 was dissolved in chloro-
form and stored at -20°C. The PAF working solution was
freshly prepared directly prior use. For this, chloroform was
evaporated under N2 and PAF was dissolved in 0.9% saline
solution containing 0.25% BSA. Female mice were challenged
with 200 mg·kg-1 PAF in a volume of 200 mL via a tail vein
injection, 30 min after an i.p. injection of either vehicle
(0.9% saline solution containing 2% DMSO), HZ52 or zileu-
ton, at the indicated doses. Death (determined by cessation of
breathing) was then recorded over a period of 2 h. All animals
surviving the 2-h test session were killed by CO2 inhalation.
Cell preparation
Human polymorphonuclear leucocytes (PMNL) were freshly
isolated from leucocyte concentrates obtained at the Blood
Center of the University Hospital Tuebingen (Germany) as
described previously (Pergola et al., 2008). In brief, venous
blood was taken from healthy adult female donors and
Figure 1
Inhibition of LO product synthesis in intact cells. (A) Chemical structures of HZ52 and HZ49. (B) PMNLs (5 ¥ 106 in 1 mL of PGC buffer) were
pre-incubated with HZ52, HZ49 or vehicle (0.3% DMSO, w/o) at the indicated concentrations for 15 min at 37°C. Then, 20 mM AA plus 2.5 mM
A23187 was added and the reaction was stopped after 10 min. The amounts of LTB4 and 5-H(P)ETE were determined by HPLC. The 100% values
correspond to 19.6  1.4 ng per 106 cells for LTB4 and 181.0  52.5 ng per 106 cells for 5-H(p)ETE. (C) PMNLs (5 ¥ 106 in 1 mL of PGC buffer)
were pre-incubated with HZ52 (left panel) or BWA4C (right panel) or vehicle (0.3% DMSO, w/o), respectively, for 15 min at 37°C. Then, 20 mM
AA plus 2.5 mM A23187 was added and the reaction was stopped after 10 min. The amounts of 12-H(P)ETE, 15-H(P)ETE, LTB4 and 5-H(P)ETE were
determined by HPLC. The 100% values correspond to 17.0  0.9 ng per 106 cells for LTB4, 123.7  11.1 ng per 106 cells for 5-H(p)ETE, 30.0 
7.3 ng per 106 cells for 12-H(p)ETE, 10.6  2.6 ng per 106 cells for 15-H(p)ETE. Data are given as mean + SEM; n = 4–5.
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leucocyte concentrates were prepared by centrifugation at
4000¥ g for 20 min at 20°C. PMNL were immediately isolated
by dextran sedimentation, centrifugation on Nycoprep cush-
ions (PAA Laboratories, Linz, Austria), and hypotonic lysis of
erythrocytes. Cells were finally resuspended in PBS pH 7.4
containing 1 mg·mL-1 glucose and 1 mM CaCl2 (PGC buffer).
Determination of product formation of 5-LO,
15-LO and 12-LO in intact cells
For assays of intact cells stimulated with Ca2+ ionophore
A23187 or NaCl, 5 ¥ 106 freshly isolated PMNL were resus-
pended in 1 mL of PGC buffer. After pre-incubation with the
indicated test compounds for 15 min at 37°C, 5-LO product
formation was started by addition of 2.5 mM A23187 and
exogenous AA as indicated or 0.3 M NaCl was added 3 min
before addition of AA. After 10 min at 37°C, the reaction was
stopped with 1 mL of methanol and 30 mL of 1 M HCl,
200 ng PGB1 and 500 mL of PBS were added. Formed 5-LO
metabolites were extracted and analysed by HPLC as
described previously (Pergola et al., 2008). 5-LO product for-
mation is expressed as nanograms of 5-LO products per 106
cells, which includes LTB4 and its all-trans isomers, 5(S),12(S)-
di-hydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid (5(S),
12(S)-DiHETE) and 5(S)-hydro(pero)xy-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-H(p)ETE). Cysteinyl LTs C4, D4
and E4 were not detected, and oxidation products of LTB4
were not determined. 15(S)-hydro(pero)xy-5,8,11-cis-13-
trans-eicosatetraenoic acid was analysed as the product
of 15-LO and 12(S)-hydro(pero)xy-5,8-cis-10-trans-14-cis-
eicosatetraenoic acid as the product of 12-LO. To assess 5-LO
product formation in PMNL stimulated with fMLP, 2 ¥ 107
freshly isolated PMNL were resuspended in 1 mL of PGC
buffer. Cells were primed with 1 mg·mL-1 LPS for 10 min at
37°C and 0.3 U Ada was added. After another 10 min, cells
were treated with HZ52 for 10 min and 1 mM fMLP was added
to start 5-LO product formation. The reaction was stopped on
ice after 5 min and cells were centrifuged (800¥ g, 10 min).
The amount of LTB4 released was determined by ELISA accord-
ing to the manufacturer’s protocol (Assay Designs, Ann
Arbor, MI, USA).
Expression and purification of human
recombinant 5-LO from Escherichia coli
Escherichia coli BL21 was transformed with pT3-5LO plasmid,
and recombinant 5-LO protein was expressed at 37°C as
described (Fischer et al., 2003). For purification of 5-LO
protein, E. coli were lysed by incubation in 50 mM triethano-
lamine HCl pH 8.0, 5 mM EDTA, soybean trypsin inhibitor
(60 mg·mL-1), 1 mM PMSF and lysozyme (500 mg·mL-1),
homogenized by sonication (3 ¥ 15 s) and centrifuged at
40 000¥ g for 20 min. To purify 5-LO, the 40 000¥ g superna-
tant (S40) was applied to an ATP-agarose column (Sigma
A2767; Deisenhofen, Germany). The column was eluted as
described previously (Fischer et al., 2003). Purified 5-LO or
S40 were immediately used for 5-LO activity assays.
Determination of 5-LO product formation in
cell-free systems
When whole cell homogenates were assayed, 5 ¥ 106 freshly
isolated PMNL were resuspended in 1 mL of PBS containing
1 mM EDTA (PBS/EDTA) and sonicated (3 ¥ 10 s). Cell homo-
genates were either used immediately for 5-LO activity assay
or centrifuged at 100 000¥ g for 1 h at 4°C and 5-LO products
in the resulting 100 000¥ g supernatant (S100) were assessed.
For determination of the activity of recombinant 5-LO, S40
from E. coli lysates (corresponding to 4 mL of E. coli culture)
or 0.5 mg of partially purified 5-LO were diluted with PBS/
EDTA. Then, 1 mM ATP was added and samples were pre-
incubated with test compounds plus additional reagents (e.g.
DTT, OAG or PLs) as indicated. After 5–10 min at 4°C,
samples were pre-warmed for 30 s at 37°C, and 2 mM CaCl2
plus AA (at the indicated concentrations) were added to start
5-LO product formation. When 13(S)-HpODE was included,
the addition occurred directly prior to CaCl2 plus AA. The
5-LO reaction was stopped after 10 min at 37°C by addition
of 1 mL of ice-cold methanol and the formed metabolites
were analysed by HPLC as described for intact cells.
Analysis of subcellular redistribution of 5-LO
PMNLs (3 ¥ 107) in 1 mL PGC buffer were preincubated for
15 min at 37°C with test compounds, stimulated with 2.5 mM
A23187 for 5 min, and chilled on ice. Alternatively, cells were
incubated with compounds in presence of 0.3 U Ada for
20 min at 37°C (no addition of any further stimulus) and
chilled on ice directly. Subcellular localization of 5-LO was
determined either by mild detergent (0.1% Nonidet P-40)
lysis (Pergola et al., 2008) or by sonication of the cells and
preparation of soluble (S100) and membrane (P100) fractions
by centrifugation at 100 000¥ g (Pergola et al., 2008), respec-
tively. 5-LO in these fractions was analysed by SDS-PAGE and
Western blotting using anti-5-LO antiserum (AK7, 1551,
kindly provided by Dr Olof Rådmark, Stockholm, Sweden).
SDS-PAGE and Western blotting
Subcellular fractions of PMNL (20 mL, each) were mixed with
5 mL of glycerol plus 0.1% bromophenolblue (1:1, vol vol-1).
After SDS-PAGE on a 10% gel and electroblot to nitrocellulose
membrane (Amersham), correct loading was confirmed by
Ponceau S staining. The membranes were blocked with 5%
BSA for 1 h at RT, washed and incubated with polyclonal
anti-5-LO antiserum over night at 4°C. After washing, mem-
branes were incubated with 1:2500 ECL Plex goat anti-rabbit
IgG-Cy5 (Amersham) for 1 h at RT. Then after washing again,
proteins were visualized by an Ettan™ DIGE imaging system
(GE Healthcare).
DPPH assay
The radical scavenger activity was assessed by measuring the
reduction of the stable free radical 2,2-diphenyl-1-
picrylhydrazyl (DPPH) (Blois, 1958) with slight modifica-
tions. Briefly, 100 mL of 1, 5, 25, 50, 100 mM HZ52 in ethanol
(corresponding to 0.1, 0.5, 2.5, 5, 10 nmol) were added to
100 mL of a solution of the stable free radical DPPH in ethanol
(50 mM, corresponding to 5 nmol), buffered with acetate to
pH 5.5, in a 96-well plate. The absorbance was recorded at
520 nm (Victor plate reader, PerkinElmer) after 30 min incu-
bation under gentle shaking in the dark. Ascorbic acid and
L-cysteine were used as reference compounds. All analyses
were performed in triplicates.
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Statistics
Data are expressed as mean  SEM. IC50 values were graphi-
cally calculated from averaged measurements at 4–5 different
concentrations of the compounds using SigmaPlot 9.0 (Systat
Software Inc., San Jose, CA, USA). Statistical evaluation of the
data was performed by one-way ANOVA followed by a Bonfer-
roni or Tukey–Kramer post hoc test for multiple comparisons
respectively. A P-value <0.05 (*) was considered significant.
Results
HZ52 exhibits anti-inflammatory efficacy
in rats and protects mice against
PAF-induced shock
Since many compounds that potently inhibited 5-LO in vitro
lacked efficacy in vivo, we first assessed the efficacy of HZ52 in
animal models related to LTs, that is, carrageenan-induced
pleurisy in rats and PAF-induced shock in mice. Injection of
carrageenan into the pleural cavity of rats caused an inflam-
matory response (within 4 h), characterized by formation of
pleural exudates containing large numbers of inflammatory
cells (Table 1). HZ52 (1.5 mg·kg-1, i.p.) given 30 min before
carrageenan significantly attenuated exudate formation
(44%) and cell infiltration (38%), and reduced LTB4 levels
(43% inhibition). Zileuton (10 mg·kg-1, i.p.), a clinically used
5-LO inhibitor, served as control and similarly reduced
exudate formation (76%), cell infiltration (41%) and LTB4
levels (66%) in the exudates (Table 1).
Previous studies have established a critical role for 5-LO
products in the acute lethal toxicity of PAF in mice (Chen
et al., 1994; Goulet et al., 1994; Byrum et al., 1997), which
thus represents a suitable model to test the in vivo efficacy of
LT-synthesis inhibitors (Lorrain et al., 2010). Administration
of 200 mg·kg-1 PAF to vehicle-treated mice caused 95% mor-
tality within 30 min, hence only one out of 20 animals sur-
vived. HZ52 at the dose of 10 mg·kg-1, but not at 1.5 or
5 mg·kg-1 (i.p.), led to survival of eight out of 10 animals
(Table 2). Treatment with the 5-LO inhibitor zileuton, at the
dose of 10 mg·kg-1 (i.p.), prior to the PAF injection resulted in
7 out of 11 mice surviving the PAF treatment. Taken together,
these results indicate that HZ52 is about equally effective as
the 5-LO inhibitor zileuton in the LT-related models of
carrageenan-induced pleurisy and PAF-induced shock.
Inhibition of 5-LO product formation by
HZ52 in cell-based models
The effectiveness of HZ52 observed in vivo motivated us to
explore its cellular and molecular pharmacology in more
detail. In accordance with our previous findings (Koeberle
et al., 2008), HZ52 inhibited 5-LO product synthesis in
human PMNL stimulated with the Ca2+ ionophore A23187
(2.5 mM) plus AA (20 mM) with an IC50 = 0.7 mM for both LTB4
and 5-H(P)ETE (Figure 1B). HZ49, the corresponding ethyl
ester of HZ52, was not active up to 30 mM (Figure 1B), indi-
cating that the free carboxylic group is essential for bioactiv-
ity. To investigate the selectivity of HZ52 for 5-LO, we
monitored the formation of 12-H(P)ETE and 15-H(P)ETE in
the PMNL incubations resulting from platelet-type 12-LO
(present in PMNL-adherent platelets) and from 12/15-LO (15-
LO-1), expressed in eosinophilic granulocytes. The amount of
12-H(P)ETE was not decreased in PMNL stimulated with
A23187 plus 20 mM AA but the formation of 15-H(P)ETE was
rather augmented (Figure 1C). A similar profile could be
observed for BWA4C (Tateson et al., 1988) used as reference
5-LO inhibitor.
Table 1
Effect of HZ52 on carrageenan-induced pleurisy in rats
Treatment Exudate volume (mL)
Inflammatory cells
(¥106) LTB4 (ng per rat)
Vehicle 0.245  0.04 55.7  5.93 0.68  0.09
HZ52 (1.5 mg·kg-1) 0.137  0.025* (44%) 34.3  2.91** (38%) 0.39  0.04* (43%)
Zileuton (10 mg·kg-1) 0.06  0.03** (76%) 32.9  5.3* (41%) 0.23  0.02*** (66%)
*P < 0.05; **P < 0.01; ***P < 0.001 versus vehicle (Student’s t-test). In parentheses, the percentages of inhibition by the test compound versus
vehicle control are shown.
Thirty minutes before intrapleural injection of carrageenan, rats (n = 10 for each experimental group) were treated i.p. with 1.5 mg·kg-1 HZ52,
10 mg·kg-1 zileuton or vehicle (DMSO 4%). Exudate volume, LTB4 and inflammatory cell accumulation in the pleural cavity were assessed 4 h
after carrageenan injection. Data are expressed as mean  SEM; n = 10.
Table 2
HZ52 protects mice against PAF-induced shock
Compound Survivors per total
Vehicle 1/20
HZ52 1.5 mg·kg-1 0/5
HZ52 5 mg·kg-1 0/5
HZ52 10 mg·kg-1 8/10
Zileuton 10 mg·kg-1 7/11
Platelet-activating factor was injected i.v. into female mice at a
dose of 200 mg·kg-1. HZ52, zileuton or vehicle control (saline
solution containing 2% DMSO) was administered i.p. 30 min
prior to PAF. The number of surviving animals and the total
number of animals tested for each group are given.
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Figure 2
Effects of HZ52 on 5-LO product formation in PMNL induced by different stimuli. (A) PMNLs (5 ¥ 106 in 1 mL of PGC buffer) were pre-incubated
with HZ52, BWA4C or vehicle (0.3% DMSO, w/o) for 15 min at 37°C and then stimulated with 2.5 mM A23187 plus the indicated amounts of
AA. After 10 min at 37°C, the reaction was stopped and 5-LO products were assessed. The 100% values correspond to 39.8  7.6, 65.7  10.7,
106.1  38.1, 227.3  59.9 and 105.9  12.2 ng per 106 cells of 5-LO products at 0, 5, 10, 20 and 40 mM AA, respectively. Values are given as
means + SEM; n = 4. (B) PMNLs (5 ¥ 106 in 1 mL of PGC buffer) were pre-incubated with HZ52 for 15 min at 37°C. Then, 2.5 mM A23187 was
added and after 10 min LTB4 was determined by HPLC. The 100% values correspond to 17.3  8.7 ng per 106 cells for LTB4. Alternatively, PMNLs
(2 ¥ 107) were primed with 1 mg·mL-1 LPS for 10 min at 37°C and 0.3 U Ada was added. After another 10 min, cells were treated with HZ52 for
10 min and 1 mM fMLP was added. The reaction was stopped on ice after 5 min and released LTB4 was determined by ELISA. The 100% values
correspond to 9.5  2.9 pg per 106 cells for LTB4. Values are given as means + SEM; n = 3. (C) PMNL (5 ¥ 106 in 1 mL of PGC buffer) were
pre-incubated with HZ52, BWA4C or ZM230487 for 15 min at 37°C. NaCl (0.3 M) was added 3 min before addition of 40 mM AA or cells were
stimulated with 2.5 mM A23187 in the presence of 40 mM AA. After 10 min at 37°C, the reaction was stopped and 5-LO products were assessed.
The 100% values correspond to 105.9  12.2 and 67.2  10.0 ng per 106 cells for 5-LO products for cells stimulated by A23187 and NaCl,
respectively. Values are given as means + SEM; n = 4; *P < 0.05 versus controls that were stimulated with A23187, ANOVA + Tukey post hoc test.
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Suppression of cellular 5-LO product formation by an
inhibitor may occur by competition with the substrate, in
particular by so-called competitive 5-LO inhibitors or FLAP
antagonists (Werz et al., 1998; Fischer et al., 2007). After
supplementation of PMNL with different amounts of exog-
enous substrate (up to 40 mM AA), however, only slight, non-
significant differences in the potency of HZ52 were observed,
and 10 mM HZ52 always produced a total suppression of 5-LO
product formation (Figure 2A). For BWA4C, exogenous AA
also slightly reduced the potency (Figure 2A), whereas for the
FLAP antagonists, licofelone and MK886, a strong loss of
efficacy was evident (Fischer et al., 2007).
Previous studies showed that the efficacy of 5-LO inhibi-
tors might depend on the stimulus (Werz et al., 1998; Fischer
et al., 2003). Elicitation of 5-LO product formation in PMNL
by the Ca2+ ionophore A23187 is due to a robust Ca2+ influx
into the cells. In contrast, the bacterial peptide fMLP (a
pathophysiologically relevant stimulus) activates cellular
5-LO via GPCR signalling due to elevated [Ca2+]i and phos-
phorylation events (Werz et al., 2002). HZ52 suppressed LTB4
formation in PMNL stimulated with fMLP [1 mM, upon
priming with 1 mg·mL-1 LPS and 0.3 U·mL-1 Ada (Pergola
et al., 2008) ] with the same potency and efficacy as with
A23187 stimulation (Figure 2B). Another means to elicit 5-LO
product formation in PMNL is the induction of hyperosmotic
cell stress that activates p38 MAPK-dependent MAPKAPK-2
which phosphorylates and thus activates 5-LO without the
need for an elevated [Ca2+]i. HZ52 (10 mM) neither induced
activation of ERK or p38 MAPK nor prevented the fMLP-
evoked activation of these kinases (data not shown). On the
other hand, such phosphorylations attenuate the efficacy of
nonredox-type 5-LO inhibitors [e.g. ZM230487 (Fischer et al.,
2003) ], and in fact when PMNL were exposed to 300 mM
NaCl plus 40 mM AA the efficacy of ZM230487 (control) was
clearly reduced whereas the potency of BWA4C was less
affected, as expected (Werz et al., 1998; Figure 2C). Also for
HZ52, the potency was decreased when PMNL were chal-
lenged by hypertonicity (Figure 2C).
HZ52 promotes 5-LO translocation to the
nuclear membrane in PMNL
After stimulation of neutrophils, 5-LO translocates from the
cytosol to the perinuclear region and becomes membrane-
associated (Radmark et al., 2007). It is assumed that the
mobile portion of 5-LO translocating to the nucleus is respon-
sible for LT synthesis. In fact, agents such as FLAP inhibitors
(Brideau et al., 1992), hyperforin (Feisst et al., 2009) or sulin-
dac sulphide (Steinbrink et al., 2010) were shown to block
5-LO translocation to the nucleus and thus, can effectively
repress 5-LO product synthesis, although inhibition of 5-LO
translocation by FLAP inhibitors might be an artefact. We
investigated the effects of HZ52 on the subcellular localiza-
tion of 5-LO by means of a crude cell fractionation using mild
detergent lysis (0.1% NP-40; compare Pergola et al., 2008).
Pre-incubation of PMNL with HZ52 (3 to 30 mM) and subse-
quent stimulation with A23187 induced a concentration-
dependent 5-LO accumulation in the nuclear fraction. In
contrast, hyperforin (30 mM) prevented the accumulation of
5-LO in the nuclear fraction (Figure 3A). Interestingly, treat-
ment of PMNL with HZ52 (10 and 30 mM) alone (in the
presence or absence of Ada) caused a distinct enrichment of
5-LO at the nuclear fraction (Figure 3B). Notably, HZ49, the
inactive ethyl ester of HZ52, had no effect on 5-LO distribu-
tion, suggesting the importance of the acidic group for this
process. Finally, PMNL were completely disrupted by sonifi-
cation after treatment with HZ52 (10 or 30 mM) and separated
into a soluble and a membraneous fraction by 100 000¥ g
centrifugation. Figure 3C shows that HZ52 directs 5-LO to the
membrane compartment.
Inhibition of 5-LO activity by HZ52 in
cell-free assays
As found before (Koeberle et al., 2008), HZ52 (but not the
corresponding ethyl ester HZ49) also inhibits 5-LO in cell-
free assays using partially purified recombinant 5-LO enzyme
Figure 3
HZ52 induces 5-LO translocation to the perinuclear membrane
region. (A, B) 5-LO was analysed in nuclear and non-nuclear fractions
of PMNL (lysed by 0.1% NP-40) or (C) in the soluble (S100) and
membrane (P100) fractions after 100 000¥ g centrifugation of lysates
obtained by sonification of PMNL by SDS-PAGE and immunoblotting
after subcellular fractionation. (A) PMNLs (3 ¥ 107 in 1 mL of PGC
buffer) were pre-incubated with HZ52 at the indicated concentra-
tions, hyperforin (30 mM) or with vehicle (0.3% DMSO) for 15 min at
37°C. Then, 2.5 mM A23187 or vehicle (0.25% DMSO) was added
and cells were incubated for another 5 min at 37°C. (B, C) PMNL
were incubated with HZ52 at the indicated concentrations, hyper-
forin (30 mM), HZ49 (30 mM) or with vehicle (0.3% DMSO) in the
presence of 0.3 U Ada for 20 min at 37°C. Results are representative
of similar results obtained in two additional independent
experiments.
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with an IC50 = 1.5 mM, implying a direct interference of the
compound with 5-LO. Since most of the direct 5-LO inhibi-
tors act in a reversible manner, we first tested whether the
reduction in 5-LO product formation by HZ52 is reversible.
Partially purified 5-LO enzyme was pre-incubated with 3 mM
HZ52. After 10-fold dilution with assay buffer, 5-LO product
formation was almost at the same level as after treatment
with 0.3 mM HZ52 without prior dilution (Figure 4A). As a
control, the inhibition of the iron ligand-type 5-LO inhibitor
BWA4C was reversed after 10-fold dilution as well
(Figure 4A).
Typically, redox-active compounds inhibit 5-LO by reduc-
ing the active-site iron to the ferrous form thus interrupting
the catalytic cycle of 5-LO. To analyse whether HZ52 pos-
sesses reducing/radical scavenging properties, the compound
was tested for its ability to reduce DPPH in the presence of a
hydrogen donor. HZ52 failed to reduce DPPH (Figure 4B)
whereas L-cysteine and ascorbic acid (serving as positive con-
trols) acted as expected.
To test whether the effect of HZ52 depends on the 5-LO
substrate concentration, the amount of AA in the cell-free
assay was varied. Interestingly, at AA concentrations7.5 mM
the IC50 values were 7 to 8 mM, whereas at AA concentrations
of 10 to 40 mM the potency of HZ52 was significantly
increased with IC50 values = 1.3 to 1.5 mM (Figure 4C). Thus,
there is a considerable shift of the efficacy between 7.5 mM
and 10 mM AA. In contrast, the potency of BWA4C was not
affected by varying the AA concentration (Figure 4C).
Among 5-LO inhibitors, the nonredox-type representa-
tives [e.g. ZM230487 (Werz et al., 1998) ] are much more
potent in intact cells (at low LOOH levels) as compared to
cell-free test systems where LOOH are abundant (Werz et al.,
1998). The ability of HZ52 to inhibit purified 5-LO (IC50 =
1.5 mM) was actually not markedly impaired versus intact
PMNL (IC50 = 0.7 mM) but a reduction was observed in PMNL
homogenates (IC50 = 9 mM) or corresponding 100 000¥ g
supernatants (S100, IC50 = 8 mM). When 1 mM DTT was
given to homogenates or S100 (to reconstitute glutathione
peroxidase activity and thus to lower the LOOH levels) the
potency of HZ52 or of BWA4C was not altered (Figure 4D),
which is in contrast to the strong shift in the potency of
ZM230487 (Werz et al., 1998). Also, in contrast to
ZM230487, addition of 13-(S)-HpODE (1 mM) did not affect
the inhibition of purified 5-LO by HZ52 (Figure 4E) or
BWA4C (not shown).
Effects of 5-LO modulatory factors on the
efficacy of HZ52
Since HZ52 lost some potency in homogenates versus isolated
5-LO, cellular components may attenuate its 5-LO inhibitory
effect. Such reduced potency in homogenates has also been
observed for hyperforin, and indeed, PC abolished 5-LO inhi-
bition by hyperforin (Feisst et al., 2009). Addition of PC
(25 mg·mL-1) to purified 5-LO slightly but significantly attenu-
ated the potency of HZ52, whereas PS had no significant
effect. The efficacy of BWA4C was marginally decreased by PC
(Figure 5A). Inhibition of purified 5-LO by HZ52 in the pres-
ence or absence of Ca2+ was instead comparable (Figure 5B),
excluding a primary interference of HZ52 with Ca2+ binding
within the C2 domain. Finally, we investigated if OAG, which
also activates 5-LO at the C2-like domain and reduces the
efficacy of hyperforin (Feisst et al., 2009), modulates the 5-LO
inhibitory effect of HZ52. OAG (30 mM) moderately impaired
the potency of HZ52 to inhibit purified 5-LO, which was not
the case for BWA4C (Figure 5C).
Discussion and conclusions
The a-substituted pirinixic acid derivative HZ52 was recently
identified as lead compound within a series of novel 5-LO

Figure 4
Inhibition of 5-LO activity by HZ52 in cell-free assays. (A) Partially purified human recombinant 5-LO (0.5 mg in 1 mL of PBS/EDTA/ATP) was
pre-incubated with 3 mM HZ52 or 0.3 mM BWA4C for 10 min at 4°C. Then, one aliquot was diluted with assay buffer 10-fold, whereas the other
one was not altered, and 20 mM AA plus 2 mM Ca2+ were added to start the reaction. For comparison, 5-LO (0.5 mg) was pre-incubated with
0.3 mM HZ52 or 0.03 mM BWA4C, and then 20 mM AA plus 1 mM Ca2+ were added (no dilution). Then, all samples were incubated for 10 min
at 37°C and 5-LO product formation was analysed as described. The 100% values correspond to 609.4  74.5 ng 5-LO products per 0.5 mg
enzyme. Values are given as means + SEM; n = 3; **P < 0.01 versus inhibition w/o dilution, ANOVA + Bonferroni post hoc test. (B) Radical scavenging
properties. HZ52, L-cysteine or ascorbic acid (at the indicated amounts) were incubated with 5 nmol DPPH in 100 mL of EtOH for 30 min at RT
and the absorbance at 520 nm was measured. Values are given as means + SEM; n = 3. (C) Partially purified 5-LO (0.5 mg in 1 mL of PBS/EDTA/ATP)
was pre-incubated with HZ52 (left panel) or BWA4C (right panel) as indicated or with vehicle (0.3% DMSO, w/o) for 5–10 min at 4°C. Samples
were pre-warmed at 37°C for 30 s and 5-LO product formation was started by addition of 2 mM CaCl2 together with AA at the indicated
concentrations. After 10 min, 5-LO product formation was determined. The 100% values correspond to 107.7  23.7, 255.8  34.1, 343.8 
19.4, 587.2  83.1, 923.4  196.11 and 499.6  258.5 ng 5-LO products per 0.5 mg of enzyme at 3, 5, 7.5, 10, 20 and 30 mM AA, respectively.
Values are given as mean + SEM; n = 3–5. (D) PMNL (5 ¥ 106) were sonicated and the homogenates or corresponding supernatants (S100) derived
from 100 000¥ g centrifugation were pre-incubated with HZ52 (left panel) or BWA4C (right panel) or vehicle (0.3% DMSO, w/o) in PBS/EDTA/ATP
at 4°C for 5 min. Then, 1 mM DTT (as indicated) was added, and after another 5 min, samples were pre-warmed at 37°C for 30 s and 5-LO
product formation was started by addition of 2 mM CaCl2 plus 20 mM AA. After 10 min, 5-LO products were determined. Inhibition of 5-LO
activity in intact PMNL is given for comparison. The 100% values correspond to 153.0  52.3, 209.0  52.6, 112.1  13.3, 140.0  22.8 and
227.3 59.9 ng 5-LO products per 106 cells in homogenates, homogenates plus DTT, S100, S100 plus DTT and intact PMNLs, respectively. Values
are given as mean + SEM; n = 3–4. (E) Partially purified 5-LO (0.5 mg) was pre-incubated with HZ52 or vehicle (0.3% DMSO, w/o) in PBS/ETDA/ATP
as indicated for 5–10 min at 4°C. Samples were pre-warmed at 37°C for 30 s and 5-LO product formation was started by addition of 2 mM CaCl2
plus 20 mM AA in presence or absence of 13(S)-HpODE (1 mM). After another 10 min, 5-LO products were assessed. The 100% values correspond
to 923.4 196.11 and 1373.9 197.4 ng 5-LO products per 0.5 mg of enzyme in the absence and presence of 13(S)-HpODE, respectively. Values
are given as mean + SEM; n = 3.
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Figure 5
Cellular components and lipids attenuate the 5-LO inhibitory potency of HZ52. (A) Partially purified 5-LO (0.5 mg in 1 mL of PBS/EDTA/ATP) was
pre-incubated with HZ52 (left panel) or BWA4C (right panel) or with vehicle (0.3% DMSO, w/o) for 5–10 min at 4°C with or without PC or PS
(25 mg·mL-1, each) as indicated. Samples were pre-warmed at 37°C for 30 s and 5-LO product formation was started by addition of 2 mM CaCl2
plus 20 mM AA. After another 10 min, 5-LO products were determined. The 100% values correspond to 874.7  290.0, 1375.0  111.3 and
897.5  96.3 ng 5-LO products per 0.5 mg of enzyme in the absence or presence of PC and PS, respectively. Values are given as mean + SEM;
n = 4–5. (B) Partially purified 5-LO (0.5 mg in 1 mL of PBS/EDTA/ATP) was pre-incubated with HZ52 or vehicle (0.3% DMSO, w/o) for 5–10 min
at 4°C. Samples were pre-warmed at 37°C for 30 s and 5-LO product formation was started by addition of 30 mM AA with or without 2 mM CaCl2.
After 10 min, 5-LO products were determined. The 100% values correspond to 1353.5  405.3 and 499.6  258.5 ng 5-LO products per 0.5 mg
of enzyme in the absence or presence of Ca2+, respectively. Values are given as mean + SEM; n = 3. (C) Partially purified 5-LO (0.5 mg in 1 mL of
PBS/EDTA/ATP) was pre-incubated with HZ52 (left panel) BWA4C (right panel) or with vehicle (0.3% DMSO, w/o) for 5–10 min at 4°C with OAG
(30 mM) or solvent (0.3% DMSO). Samples were pre-warmed at 37°C for 30 s and 2 mM CaCl2 plus 20 mM AA was added. After another 10 min,
5-LO products were determined. The 100% values correspond to 1155.6  138.3 and 801.9  124.3 ng 5-LO products per 0.5 mg of enzyme
in the absence or presence of OAG respectively. Data are means + SEM; n  3; *P < 0.05 versus controls without OAG (w/o) at corresponding
concentrations of test compounds, ANOVA + Tukey post hoc test.
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inhibitors with distinct SARs (Koeberle et al., 2008; Werz
et al., 2008). Here, we assessed the in vivo efficacy and anti-
inflammatory activity of HZ52, and we characterized its phar-
macological profile in order to judge the value of further
development. The efficacy of HZ52 in the rat pleurisy and in
the murine model of PAF-induced shock clearly proves that it
has in vivo activity. Our biochemical analysis revealed HZ52
to be a novel type of direct 5-LO inhibitor with distinct
characteristics as compared to classical redox-type, iron
ligand-type, nonredox-type inhibitors or 5-LO C2-like
domain inhibitors. Obviously, certain disadvantages of other
types of 5-LO inhibitors that blighted their successful devel-
opment were less noticeable in HZ52, thus indicating a
favourable profile and encouraging pharmacodynamic fea-
tures of HZ52 worthy of further development as an anti-
inflammatory drug.
Numerous small molecules from natural sources and of
synthetic origin have been described during the past three
decades as 5-LO product synthesis inhibitors (Werz, 2007;
Pergola and Werz, 2010). However, despite the huge number
and strong diversity of such compounds only zileuton, a
hydroxurea derivative chelating and reducing the active site
iron in 5-LO (Carter et al., 1991), has been approved by the
FDA and reached the market. Many compounds were not
further developed based on their lack of efficacy in vivo and
low therapeutic potential for treatment of LT-related diseases
(Peters-Golden and Henderson, 2007). Apparently, the dis-
tinct conditions at sites of inflammation hampered the effi-
cacy of these substances in vivo (Werz and Steinhilber, 2005).
Our previous studies revealed that HZ52 is a direct 5-LO
inhibitor with high potency in cell-free and cell-based in vitro
assays. Thus, HZ52 inhibited the activity of isolated 5-LO
with IC50 = 1.5 mM and blocked 5-LO product formation in
intact PMNL stimulated with A23187 in the presence of exog-
enous AA with an IC50 = 0.7 mM (Koeberle et al., 2008). Here,
we show that HZ52 suppresses 5-LO product synthesis in vivo,
visualized by the reduced LTB4 levels in the pleural exudates
of carrageenan-treated rats after a low-dose treatment,
1.5 mg·kg-1, and this was accompanied by a significant reduc-
tion in the inflammatory response. In addition to the pleurisy
model, which is a routine test system for evaluation of LT
synthesis inhibitors (Ku et al., 1988; Smith et al., 1992; Ray-
chaudhuri et al., 1997; Cuzzocrea et al., 2003), we used
another 5-LO-related disease model, that is, PAF-induced
lethal shock in mice (Chen et al., 1994; Goulet et al., 1994;
Byrum et al., 1997). This model is used as predictive in vivo
test system for analysis of anti-LTs (Lorrain et al., 2010). For
both carrageenan-induced pleurisy and PAF-induced shock,
studies with 5-LO-deficient mice revealed a significant func-
tional role of 5-LO (Chen et al., 1994; Cuzzocrea et al., 2003).
Indeed, HZ52 significantly protected the mice treated with
PAF against the lethal shock, and side-by-side comparison
with zileuton at the same dose (i.e. 10 mg·kg-1) shows an
equal or even higher efficacy for HZ52. The equivalent effi-
cacy in vivo is reflected by comparable IC50 values of HZ52
(0.4–1 mM) and zileuton [0.5–1 mM (Carter et al., 1991) ] in
various cell-based 5-LO activity assays in vitro. Hence, our
data allow us to designate HZ52 as a direct 5-LO inhibitor
with considerable efficacy in vivo. Although the blood–brain
permeability of HZ52 is not known, its lipophilic structure
suggests availability in the brain, which is of interest with
respect to the proposed beneficial effects of 5-LO inhibitors in
Alzheimer’s disease (Chu and Pratico, 2011).
Direct 5-LO inhibitors can be classified into redox-active
substances, iron-ligand inhibitors, nonredox-type inhibitors
and compounds with different modes of action (Pergola and
Werz, 2010). Based on our data, HZ52 cannot be unequivo-
cally grouped into one class suggesting a novel, thus far
unrecognized molecular mode of action for its ability to inter-
fere with 5-LO activity. Direct interference with ionophore
can be excluded since HZ52 suppressed 5-LO product forma-
tion induced by LPS and fMLP almost equally well. Since
HZ52 inhibited cellular 5-LO product synthesis in the
absence or presence of 20 mM exogenous AA equally well, we
suggest that suppression of release of AA is also unlikely.
Redox-active 5-LO inhibitors are highly potent in vitro but
most of them were not further developed due to rapid inac-
tivation in vivo and lack of selectivity (McMillan and Walker,
1992; Hutchinson et al., 1995). Thus, interference with other
redox systems caused unwanted toxic side effects (McMillan
and Walker, 1992). The lack of moieties with reducing prop-
erties in the overall structure of HZ52 and the failure to
exhibit any radical scavenging/reducing effect in the DPPH
assay obviously exclude a redox- or radical scavenging-based
5-LO inhibitory mechanism. Also, no typical iron-chelating
moiety of prototype iron-ligand inhibitors [e.g. hydroxamic
acid in BWA4C (Tateson et al., 1988) or hydroxyurea in zileu-
ton (Carter et al., 1991) ] is evident. Along these lines, HZ52
failed to inhibit the iron-containing and redox-sensitive 12-
and 15-LOs.
In contrast to nonredox-type inhibitors [e.g. ZM230487,
L-739.010 and CJ-13.610 (Werz et al., 1998; Fischer et al.,
2004) ], suppression of 5-LO activity by HZ52 was not influ-
enced by elevated peroxide levels or by the redox tone. This
is an advantageous property of HZ52, since oxidative stress
and an altered redox tone are often associated with LT-related
diseases and compromise the efficacy of nonredox-type 5-LO
inhibitors [see Werz et al. (1998) and references therein]. In
intact PMNL, HZ52 inhibited 5-LO product synthesis equally
well when stimulated by LPS plus fMLP or by A23187, which
is again in contrast to nonredox-type 5-LO inhibitors that are
more efficient in A23187-elicited PMNL (Fischer et al., 2003).
On the other hand, HZ52 shares with nonredox-type 5-LO
inhibitors a reduced potency in PMNL challenged by hyper-
tonic stress.
HZ52 also showed some characteristics of the C2-like
domain inhibitor hyperforin. For example, in contrast to
BWA4C, the interference of HZ52 with 5-LO was partly
reversed by PC (but not by PS) or OAG, and cellular compo-
nents (present in homogenates) impaired the potency of
HZ52 as well. However, the magnitude of modulation of
HZ52-mediated 5-LO inhibition by these factors was mark-
edly weak. Depletion of Ca2+ in cell-free assays did not alter
the profile of HZ52. Therefore, we exclude an interference of
HZ52 with the Ca2+-binding residues within the C2-like
domain of 5-LO. Also, HZ52 did not prevent Ca2+-mediated
nuclear 5-LO translocation and membrane association,
another property of C2 domain-interfering agents (Kulkarni
et al., 2002; Feisst et al., 2009). In contrast, HZ52 caused redis-
tribution of 5-LO from the cytosol towards the perinuclear
(membrane) region, and this occurred in the absence or pres-
ence of any stimulus. Similarly, thiopyrano[2,3,4-c,d]indoles,
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a class of dual 5-LO/FLAP inhibitors, promoted translocation
of 5-LO to the nuclear membrane also in the absence of any
stimulus (Hutchinson et al., 1995). Nevertheless, higher con-
centrations of HZ52 were needed to induce nuclear redistri-
bution (10 to 30 mM) compared to those required to
substantially inhibit 5-LO product synthesis in A23187 or
fMLP/LPS-stimulated PMNL (IC50 = 0.4–0.7 mM), suggesting
that the redistribution is probably not the primary cause for
5-LO inhibition in PMNL. Together these results suggest that
HZ52 primarily acts by distinct mechanisms other than inter-
ference with the functionality of the 5-LO C2-like domain.
One of the remarkable characteristics of HZ52 is that its
potency in the cell-free assay depends on the substrate con-
centration, in that HZ52 possessed a definite lower potency
(IC50 = 7–8 mM) at AA concentrations <7.5 mM and high
potency (IC50 = 1.3–1.5 mM) at AA concentrations 10 mM.
This pattern was not observed for BWA4C in the present
study, and we are not aware of other 5-LO inhibitors that
show such characteristics. Possibly, AA at concentrations
10 mM positively modulates 5-LO activity at a second,
stimulating AA-binding site (Aharony and Stein, 1986; Ham-
marberg et al., 2001; Burkert et al., 2003) and this might be
effectively blocked by HZ52. Alternatively, at concentrations
10 mM, AA may form micelles or lipid vesicles that favour
the incorporation of HZ52 and thus allow more efficient
access of the inhibitor towards 5-LO. Interestingly, in intact
PMNL, HZ52 consistently inhibited 5-LO with IC50 = 0.4 to
1 mM up to 40 mM AA, indicating that the AA-dependent,
distinct high and low potencies of HZ52 in the cell-free assay
are not evident in intact cells. Together, our data indicate that
HZ52 does not act by classical competition with AA as sub-
strate at the active site but it may interfere with an allosteric
site affected by AA.
In conclusion, our data reveal HZ52 to be a novel type of
selective and effective 5-LO inhibitor in vitro and in vivo with
marked efficacy in animal models of diseases that involve LTs.
Importantly, HZ52 does not act as redox-active agent or iron-
ligand inhibitor and does not exhibit the disadvantages of
nonredox-type 5-LO inhibitors, such as loss of potency at
elevated oxidative tone or strong dependency on the stimu-
lus. These features confer on HZ52 great potential as a prom-
ising lead candidate for further preclinical assessment as
a pharmacological agent for the treatment of LT-related
disorders.
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